<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:hpo ids='HP_0002140'>Ischemic stroke</z:hpo> continues to be one of the main causes of <z:hpo ids='HP_0011420'>death</z:hpo> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0001845'>Inflammation</z:mp> accounts for a large part of damage in this pathology </plain></SENT>
<SENT sid="2" pm="."><plain>The cannabinoid type 2 receptor (CB2R) has been proposed to have neuroprotective properties in <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurological diseases</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, our aim was to determine the effects of the activation of CB2R on <z:mpath ids='MPATH_124'>infarct</z:mpath> outcome and on <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced brain expression of classic and alternative markers of macrophage/microglial activation </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Swiss <z:mp ids='MP_0002169'>wild-type</z:mp> and CB2R knockout male mice were subjected to a permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Mice were treated with either a CB2R <z:chebi fb="4" ids="48705">agonist</z:chebi> (JWH-133), with or without a CB2R <z:chebi fb="68" ids="48706">antagonist</z:chebi> (SR144528) or vehicle </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> outcome was determined by measuring <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and neurological outcome </plain></SENT>
<SENT sid="7" pm="."><plain>An additional group of animals was used to assess <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression of CB2R, interleukin (IL)-1β, IL-6, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor α (TNF-α), monocyte chemoattractant protein-1 (<z:chebi fb="17" ids="50099">MCP</z:chebi>-1), macrophage inflammatory <z:chebi fb="7" ids="16670">peptide</z:chebi> (MIP) -1α, RANTES, inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (iNOS), cyclooxygenase-2, IL-4, IL-10, transforming growth factor β (TGF-β), arginase I, and Ym1 </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Administration of JWH-133 significantly improved <z:mpath ids='MPATH_124'>infarct</z:mpath> outcome, as shown by a reduction in <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> and neurological impairment </plain></SENT>
<SENT sid="9" pm="."><plain>This effect was reversed by the CB2R <z:chebi fb="68" ids="48706">antagonist</z:chebi> and was absent in CB2R knockout mice </plain></SENT>
<SENT sid="10" pm="."><plain>Concomitantly, administration of JWH-133 led to a lower intensity of Iba1+ microglia/macrophages and a decrease in middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>-induced gene expression of both classic (IL-6, TNF-α, <z:chebi fb="17" ids="50099">MCP</z:chebi>-1, MIP-1α, RANTES, and iNOS) and alternative mediators/markers (IL-10, TGF-β, and Ym1) of microglial/macrophage activation after permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: The inhibitory effect of CB2R on the activation of different subpopulations of microglia/macrophages may account for the protective effect of the selective CB2R <z:chebi fb="4" ids="48705">agonist</z:chebi> JWH-133 after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>